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Abstract 
Rheumatoid arthritis is a chronic inflammatory disorder that typically affects the small joints in hands and feet. 
Genes involved in T-cell regulation are potential candidates. Association to cytotoxic T-lymphocyte-associated-4 
(CTLA-4) protein, a negative regulator of T-cell activation, has previously been described in Rheumatoid 
arthritis patients. In this study, our aim was to determine the role of CTLA-4 polymorphism among patients with 
Rheumatoid arthritis. A total of 120 Rheumatoid arthritis patients (69 males and 51 females) with an age mean ± 
SD (67.2000± 11.74133), family history (16 positive/ 104 negative), rheumatoid factor test (RF) (43 positive/ 77 
negative), Anti-CCP antibody test (120 positive/ 0 negative), and 120 controls (46 males and 74 females) of 
Iraqis ethnicity with an age mean ± SD (31.6583± 11.51579). There was no significant difference between the 
groups (Rheumatoid arthritis patients and their control) (P = 0.478). And CTLA-4 gene polymorphism in each 
group was compared (AA, GG, AG). There is no difference between the CTLA-4 (SNP +49 A/G rs#231775) 
gene polymorphism among Rheumatoid arthritis patients and healthy people.  
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Introduction   
Rheumatoid arthritis (RA) is a complex autoimmune disorder, characterized by a chronic T-cell response that 
has evaded normal control mechanisms (GORONZY and WEYAND 2004). Also is characterized by chronic 
inflammation of the joint, which may lead to structural damage of the cartilage and bone (SINGAL et al. 1999). 
Actually in RA both environmental and genetic factors contribute to the disease, with the later being a 
substantial contributory factor in the pathogenesis of the disease (JOHN and WORTHINGTON 2001; MACGREGOR 
et al. 2000). A many genes contributed to RA susceptibility has been found, among all these genes, HLA-DR 
loci was most thoroughly studied yet HLA-DR accounts only for approximately one-third of the genetic 
susceptibility to RA. Other loci also implicated in the predisposition to RA, such as CTLA4, PADI4, PTPN22, 
TNF-a, IL-1b and STAT4, account for relatively small additional contribution RA genetic susceptibility (KURKO 
et al. 2013). It has been reported that CTLA-4 polymorphisms are associated with several T-cell mediated 
autoimmune diseases, such as Graves’ disease, type 1 diabetes mellitus (T1D) and multiple sclerosis (KANTARCI 
et al. 2003; KOUKI et al. 2002; MARRON et al. 2000). The CTLA-4 encodes the T cell receptor involved in the 
control of T cell proliferation and mediates T cell apoptosis (WATERHOUSE et al. 1995). The human CTLA-4 
gene was mapped to chromosome 2q33 (DARIAVACH et al. 1988). Most molecular epidemiology studies have 
evaluated the role of the + 49A/G (rs#231775) single nucleotide polymorphism (SNP) that causes a threonine-
toalanine substitution in codon 17 and is associated with altered protein expression (ANJOS et al. 2002). The aim 
of this study was to examine the role of Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) +49 gene in 
genetic susceptibility as a risk factors for rheumatoid arthritis (RA) in a sample of Iraqis patient. 
 
Materials and methods 
120 patients with an established diagnosis of RA, (69 males and 51 females) with an age mean ± SD (67.2000± 
11.74133), family history (16 positive/ 104 negative), rheumatoid factor test (RF) (43 positive/ 77 negative), 
Anti-CCP antibody test (120 positive/ 0 negative). and 120 controls (46 males and 74 females) of Iraqis ethnicity 
with an age mean ± SD (31.6583± 11.51579), were enrolled in this study and recruited at Baghdad teaching 
hospital, medical city, Baghdad, Iraq. patients with RA [diagnosed based on American Rheumatism Association 
(ACR) 1987 Criteria (ARNETT et al. 1988). The ethics committees of participating universities and university 
hospitals approved the study, and informed consent was obtained from all participants. Blood sampling (one ml 
of venous blood) was collected in EDTA tubes from each individual (patient or healthy control) and was stored 
as whole blood at -20oC for subsequent DNA isolation. Genomic DNA was isolated from whole blood according 
to Sambrook et al 1989 (SHUBEITA et al. 1987). 
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Genotyping of (CTLA-4) +49 gene polymorphism  
One SNP (rs#231775 A/G) CTLA-4 gene was genotyped among the participants groups in this study. The 
CTLA-4 A/G polymorphic region (rs#231775 A/G) was amplified by polymerase chain reaction (PCR) using 
allele specific PCR technique as shown in Table 1. Three primers (two allele specific primers and common 
reverse primer) were designed based on the nucleotide sequence of a partial fragment (retrieved from the online 
dbSNP) of the gene containing the target SNP. The polymorphism was visualized by separating the DNA 
fragments in a 2% agarose gel that was stained with ethidium bromide and illuminated by UV. To validate the 
PCR- allele specific results to validate the PCR- allele specific results. All primers used in this study were newly 
designed using Primer Blast online programme (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1:2% agarose gel electrophoresis for allele specific PCR for CTLA-4 gene (rs#231775 A/G) M: 
100 bp DNA ladder from GeneDireX®. Lanes 1 and 2: PCR products upon using allele specific C primer and 
allele specific T primer, respectively. Heterozygous genotype will give positive reaction upon using both allele 
specific primers. However, homozygous genotype will give positive reaction upon using only one of these allele 
specific primers. 
Table 1: Primers sequences, PCR conditions, length of PCR products 
 
Statistical analysis of data 
Statistical analysis of data was done to correlate genotype distribution and allele frequencies were performed by 
SPSS package version 17. The frequencies of alleles, genotypes in different groups were compared using the 
Chi-squared test (X2), t-test were used to test the significance of results of quantitative variables. Odds ratio and 
95% confidence interval (95% CIs) were calculated for different studied parameters. The confidence interval (CI) 
at 95% was used to describe the amount of uncertainty associated with the samples (GREENFIELD et al. 2008; 
SZUMILAS 2010).  The significance of the results was taken at the P < 0.05 level of significance. 
 
Results and Discussion 
Results revealed that the allele and  genotypic  distributions  did  not  significantly  differ  between  the  two  
groups  (P>0.05)  for  the  SNP-  CTLA-4 +49 A ⁄ G (rs#231775) as shown in table 2. 
SNPs Primers sequences PCR Conditions Size of PCR 
Products 
digestion products 
CTLA-4  
SNP49 
G/A 
(rs#231775) 
A-allele specific primer: 
F1: 5-GCTCAGCTGAACCTGGCT A -3    
 
G-allele specific primer: 
F2: 5-GCTCAGCTGAACCTGGCT G-3     
 
Common reverse primer: 
5-CTTTAACTTCTGGCTTTGCTAT-3      
 
An initial denaturation  at 
95oC for 5 min  
-Then, 30 cycles each 
cycle consisted of 
denaturation at 94oC for 
60s, annealing at 50 oC for 
30s and extension at 72oC 
for 30 s.  
-A final extension at 72oC 
for 10min. 
  Allele A:  189 bp 
  Allele G: 189 bp  
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Table 2: CTLA-4 gene polymorphism and allele frequencies among RA patients and their control 
Gene 
polymorphism 
Cases Control 
Significance OR (95% CI) 
No. % No. % 
CTLA-4  
SNP49 
G/A 
(rs#231775) 
    
X2 = 0.504 
P = 0.478 
 
AA 25 26.6 49 40.9 (0.761 - 1.729) 
GG 49 40.9 24 20.0 (0.578 - 1.314) 
AG 39 32.5 47 39.1  
X2: Chi-Square test                       *significant at P≤0.05     
The RA is a T-cell-mediated autoimmune disease (LORBER et al. 1994). Many genes discovered 
contributed in autoimmune diseases in murine models (VYSE and TODD 1996). Some genes determine the 
susceptibility of a target organ to an immune response. CTLA-4 is a prime candidate autoimmunity gene leading 
to alteration in function could have profound effects on the immune system. Defective CTLA-4 expression could 
result in failure to terminate T-cell activation (BARTON et al. 2000). 
Our results corresponded with Barton, A. et al. Noted that no significant differences in the frequency 
of the G allele or the GG genotype were found in either the UK or Spanish RA patients compared with controls 
(BARTON et al. 2000). Previous study approved that the CTLA-4 gene is associated with Japanese patients with 
RA carrying the susceptible HLA allele; AG genotype occurred more frequently in patients with RA in Japanese 
population  (59 vs 44%) (YANAGAWA et al. 2000).This result agree with Lee, C.S. et al. that suggested the 
CTLA4 49 A-G polymorphism is associated with RA in Chinese patients from Taiwan, genotype CTLA4 49 
G/G and allele G were associated with an increased risk of RA, whereas genotype A/G and allele A were 
associated with protection against RA (LEE et al. 2003).  
A total of 30 case-control studies in 20 articles were included in this meta-analysis study found that the 
+49A/G and CT60 polymorphisms in the CTLA-4 gene may be risk factors for RA according to the results and 
that showed the variant G allele carriers (GG + GA) of +49A/G polymorphism had an 18% increased risk of RA 
when compared with the homozygote AA. 
 In addition, the variant CT60A allele carriers of CT60 polymorphism had a 14% decreased risk of RA 
when compared with the homozygote GG. In the subgroup analysis by ethnicity, significant elevated RA risks 
were associated with +49G allele carriers in Asians, but not in Europeans. However, for CT60 polymorphism, 
significant decreased RA risks were associated with CT60 A allele carriers in Europeans, but not in Asians(LI et 
al. 2012). Other meta-analysis corresponded with previously meta-analysis studies, which suggest CTLA-4 
A49G polymorphism was associated with RA risk. The researchers attempted to perform an updated meta-
analysis of available case–control study in order to assess the association between CTLA-4 A49G polymorphism 
and RA risk by searched the various citation databases, totally compiled 27 studies in 24 articles (9805 RA 
patients and 10691 control subjects) in this  meta-analysis work. A significant association between CTL-A4 
A49G polymorphism and RA risk (GG vs. AA: OR = 1.13, 95% CI = 1.03–1.23; GA vs. AA: OR = 1.19, 95% 
CI = 1.07–1.33; GA + GG vs. AA: OR = 1.18, 95% CI = 1.07–1.29). In the subgroup analysis by ethnicity, 
evidences of significantly increased risk was also found in both Asian (GG vs. AA: OR = 1.34, 95% CI = 1.15–
1.55; GA + GG vs. AA: OR = 1.24, 95% CI = 1.08–1.41) and Caucasian population (GA vs. AA: OR = 1.19, 
95% CI = 1.03–1.37; GA + GG vs. AA: OR = 1.14, 95% CI = 1.01–1.29) (LI et al. 2014) .   
Our conclusion, we found there is no association between CTL-A4 A49G gene polymorphism and RA 
among Iraqis population. 
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